Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
5.63
0.00 (-0.09%)
Apr 29, 2026, 11:45 AM EDT - Market open
Kalaris Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -43.44 | -69.17 | -14.7 | -15.49 |
| Depreciation & Amortization | 0.01 | - | - | - |
| Other Amortization | 0.19 | 38.02 | 0.89 | 1.99 |
| Asset Writedown & Restructuring Costs | - | - | - | 0.16 |
| Loss (Gain) From Sale of Investments | -0.4 | - | - | - |
| Stock-Based Compensation | 1.94 | 0.9 | 0.15 | 0.27 |
| Other Operating Activities | -0.1 | 11.71 | 0.62 | -0.11 |
| Change in Accounts Payable | -0.09 | -1.03 | -0.4 | 1.83 |
| Change in Other Net Operating Assets | 3.52 | -1.1 | -0.69 | 1.57 |
| Operating Cash Flow | -38.37 | -20.67 | -14.13 | -9.78 |
| Capital Expenditures | -0.2 | - | - | - |
| Investment in Securities | -19.52 | - | - | - |
| Investing Cash Flow | -19.72 | - | - | - |
| Short-Term Debt Issued | 7.5 | 19.97 | - | - |
| Long-Term Debt Issued | - | - | 6 | 4.3 |
| Total Debt Issued | 7.5 | 19.97 | 6 | 4.3 |
| Net Debt Issued (Repaid) | 7.5 | 19.97 | 6 | 4.3 |
| Issuance of Common Stock | 42 | 0 | - | 0.01 |
| Other Financing Activities | 105.51 | -2.42 | - | - |
| Financing Cash Flow | 155.01 | 19.14 | 14.24 | 12.78 |
| Net Cash Flow | 96.91 | -1.53 | 0.11 | 3 |
| Free Cash Flow | -38.57 | -20.67 | -14.13 | -9.78 |
| Free Cash Flow Per Share | -2.53 | -15.47 | -2.33 | -2.20 |
| Levered Free Cash Flow | -23.19 | -18.82 | -9.43 | - |
| Unlevered Free Cash Flow | -22.36 | -31.39 | -9.34 | - |
| Change in Working Capital | 3.43 | -2.13 | -1.09 | 3.4 |
Source: S&P Capital IQ. Standard template.
Financial Sources.